UNDERSTAND PATIENTS WITH SIMULATED CELLS™

UNLOCK CURES

FIND THE BEST RESPONDERS

OVERCOME RESISTANCE

RATIONALIZE R&D

alan-barge

Alan Barge

ex VP and Head of Oncology and Infection at AstraZeneca

“We believe Turbine can fundamentally change the way in which novel targets in precision oncology are identified.”

arrow-down

Simulations capture patient biology where experiments fail

Drug discovery is limited by our tools to understand disease

Conventional in vitro and in vivo models cannot capture disease behavior in real patients, and tools – like CRISPR – don’t act like actual drugs. This makes it incredibly hard to translate preclinical hypotheses to the clinic and create targeted drugs that truly help.

Simulations uncover treatments and the patients who benefit

Before running any wet lab experiments, Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. Simulations can reveal the right modality and combination approach to treat even the most resistant cancers. Observing these in silico experiments our biologists and translational experts gain insight into the molecular context by which mono- and combination therapies can potentially lead to patient benefit. Simulations are used to select the right preclinical models, as well as the right patients to confirm the predicted mechanisms, targets, biomarkers & combinations.

https://pubmed.ncbi.nlm.nih.gov/14518029/
https://www.nature.com/articles/s41467-021-25175-5
globaldata.com

Engineering a way to understand biology

platform1

The world’s first interpretable cell simulation platform augmented by machine learning

Pioneering an approach that combines simulation with machine learning, we map and model how thousands of signaling proteins interact characterizing cancer behavior at a cellular level and response or resistance to treatment.

Our platform enables us to simulate drug-like effects from compoundsthat may not exist yet, on cells potentially unavailable for lab-based testing, like those of cancer patients.

Predict truly novel experiments to find drugs no-one has ever thought of

This approach will potentially allow us to predict not only what works in cells, mice and people but more importantly, why and how. Continuous iterations of simulations and proprietary in vitro and in vivo experiments confirm predictions and progress our pipeline while simultaneously improving the underlying Simulated Cell™. As all programs and partnerships run on the latest version of the in silicocell, model training benefits accumulate, leading to a constantly improving platform. Using results to both generate the initial idea and to guide its iterations, as the models improve, this leads to a more rational process to undestand the underlying disease biology. Our benchmarks show that simulations prevent 2 out of 3 failed experiments in vitro and every 2nd failure in vivo as well.

platform2

A single platform to rationalize the entire R&D process

Simulated Cells™ can be used to run the equivalent of any preclinical or clinical protocol, at computational speed and scale. Running millions of simulations before conducting the most promising wet experiments, Turbine’s platform guides every step from target ID to clinical Proof of Concept.

The Simulated Cell™ has already been validated from target discovery to patient stratification and life cycle management in collaboration with multiple big pharma companies as well as in our proprietary pipeline.

THE SIMULATION-GUIDED DRUG DISCOVERY AND DEVELOPMENT PROJECT

Understand the disease

Simulating cancer behavior to understand drivers of disease & mechanisms of resistance observed in clinical settings

Find the ideal patients

Uncovering ideal patient population and combination strategy for therapies already in development or on the market

Expand the search space

Identifying truly novel targets to manage unmet need in patients who don’t benefit from existing therapies

picto1

FIND THE IDEAL PATIENTS AND INDICATIONS

Benefit of using Simulated Cells™?

  • Identify biomarkers of sensitivity or resistance for patient stratification in clinical trials
  • Design combination therapies to increase efficacy & delay resistance
  • Expand indication space as single or combination therapy

picto2

EXPAND THE SEARCH SPACE TO ID NOVEL TARGETS FOR RESISTANT PATIENTs

Benefit of using Simulated Cells™?

  • Identify novel targets, the right modality to act on them and molecular markers of response to assess upside potential & differentiate against competing therapies
  • Deconvolute mechanism of action to guide drug discovery, indication finding & molecule optimization
  • Identify pharmacodynamic markers to guide drug development and optimize candidate molecules

Building deep tech for deep biology

Building an engineer’s toolkit to understand biology requires software and data scientists who wish to enable biological translational science instead of replacing it. Our team combines the amazing molecular biology, network- and data science expertise in Hungary with seasoned drug developers from the UK and the US. We’re here to change the status quo and bring truly impactful, simulation-guided therapies to patients.

Founders and management

BOARD AND ADVISORS

UNDERSTAND PATIENTS WITH SIMULATED CELLS™

UNLOCK CURES

FIND THE BEST RESPONDERS

OVERCOME RESISTANCE

RATIONALIZE R&D

cell

Trusted By

partner1partner2partner3partner4partner5partner6partner7partner8partner9partner10partner11partner12